Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
MAGS vs XBI: how they differ
MAGS and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
Roundhill Magnificent Seven ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, MAGS and XBI hold 0% of their money in the same securities at the same weight.
| Only in MAGS | Only in XBI |
|---|---|
| TREASURY BILL 65.41% | Apogee Therapeutics Inc 1.49% |
| Roundhill Ultra Short Duration 8.06% | Moderna Inc 1.41% |
| NVIDIA Corp 4.15% | Twist Bioscience Corp 1.41% |
| Apple Inc 4.12% | Oruka Therapeutics Inc 1.38% |
| Amazon.com Inc 4.11% | Kymera Therapeutics Inc 1.36% |
| Tesla Inc 4.07% | Viking Therapeutics Inc 1.31% |
| Microsoft Corp 3.62% | Praxis Precision Medicines Inc 1.29% |
| Meta Platforms Inc 3.59% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
| MAGS Roundhill Magnificent Seven ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Roundhill | State Street |
| What it is | Magnificent Seven | SPDR S&P Biotech |
| Total return, 1 year | +14.4% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −3.1 pts | +46.5 pts |
| Expense ratio | 0.30% | 0.35% |
| Already in the S&P 500 | 26.5% | 8.5% |
| Holdings | 9 | 150 |
MAGS in plain words
MAGS is an index equity fund tracking the Magnificent Seven. Over the year to Sep 11, 2026 it returned +14.4% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.30% a year. By its holdings filed for Jun 30, 2026, 26% of the fund by weight is stocks the S&P 500 also holds, across 9 positions, with the top ten at 100.0%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, MAGS or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, MAGS returned +14.4% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, MAGS or XBI?
- MAGS charges 0.30% a year and XBI charges 0.35%, so MAGS is cheaper. Fees come from each fund's prospectus.
- How much do MAGS and XBI overlap with the S&P 500?
- By their latest filed holdings, 26% of MAGS and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, MAGS against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/MAGS-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources